Skip to main content

Johnson & Johnson beats on earnings, hikes full-year guidance as medtech sales surge

The results come amid investor anxiety over the thousands of lawsuits claiming that J&J's talc-based baby powder and other products caused cancer.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.